| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Gastrointestinal Research Group, Diabetes and Endocrine Research Group, and Department of Histopathology, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada; Division of Developmental Immunology, La Jolla Institute For Allergy and Immunology, San Diego, CA 92121; and ¶ Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109
Fulminant liver failure (FLF) consists of a cascade of events beginning with a presumed uncontrolled systemic activation of the immune system. The etiology of FLF remains undefined. In this study, we demonstrate that CCR5 deficiency promotes the development of acute FLF in mice following Con A administration by preventing activated hepatic CD1d-restricted NKT cells (but not conventional T cells) from dying from activation-induced apoptosis. The resistance of CCR5-deficient NKT cells from activation-induced apoptosis following Con A administration is not due to a defective Fas-driven death pathway. Moreover, FLF in CCR5-deficient mice also correlated with hepatic CCR5-deficient NKT cells, producing more IL-4, but not IFN-
, relative to wild-type NKT cells. Furthermore, FLF in these mice was abolished by IL-4 mAb or NK1.1 mAb treatment. We propose that CCR5 deficiency may predispose individuals to the development of FLF by preventing hepatic NKT cell apoptosis and by regulating NKT cell function, establishing a novel role for CCR5 in the development of this catastrophic liver disease that is independent of leukocyte recruitment.
This article has been cited by other articles:
|
|
 |
|
  D H Adams, B Eksteen, and S M Curbishley Immunology of the gut and liver: a love/hate relationship Gut, June 1, 2008; 57(6): 838 - 848. [Full Text] [PDF]
|
|
|
|
 |
|
 W. G. Nichols, H. M. Steel, T. Bonny, K. Adkison, L. Curtis, J. Millard, K. Kabeya, and N. Clumeck Hepatotoxicity Observed in Clinical Trials of Aplaviroc (GW873140) Antimicrob. Agents Chemother., March 1, 2008; 52(3): 858 - 865. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Ajuebor Role of NKT Cells in the Digestive System. I. Invariant NKT cells and liver diseases: is there strength in numbers? Am J Physiol Gastrointest Liver Physiol, October 1, 2007; 293(4): G651 - G656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Holst, C. Orskov, K. Qvortrup, J. P. Christensen, and A. R. Thomsen CCR5 and CXCR3 Are Dispensable for Liver Infiltration, but CCR5 Protects against Virus-Induced T-Cell-Mediated Hepatic Steatosis J. Virol., September 15, 2007; 81(18): 10101 - 10112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Cornwell and R. G. Ulrich Investigating the Mechanistic Basis for Hepatic Toxicity Induced by an Experimental Chemokine Receptor 5 (CCR5) Antagonist Using a Compendium of Gene Expression Profiles Toxicol Pathol, June 1, 2007; 35(4): 576 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Ajuebor, Z. Wondimu, C. M. Hogaboam, T. Le, A. E.I. Proudfoot, and M. G. Swain CCR5 Deficiency Drives Enhanced Natural Killer Cell Trafficking to and Activation within the Liver in Murine T Cell-Mediated Hepatitis Am. J. Pathol., June 1, 2007; 170(6): 1975 - 1988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Thio, J. Astemborski, A. Bashirova, T. Mosbruger, S. Greer, M. D. Witt, J. J. Goedert, M. Hilgartner, A. Majeske, S. J. O'Brien, et al. Genetic Protection against Hepatitis B Virus Conferred by CCR5{Delta}32: Evidence that CCR5 Contributes to Viral Persistence J. Virol., January 15, 2007; 81(2): 441 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Ajuebor, J. A. Carey, and M. G. Swain CCR5 in T Cell-Mediated Liver Diseases: What's Going On? J. Immunol., August 15, 2006; 177(4): 2039 - 2045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Grayson and M. J. Holtzman Chemokine Complexity: The Case for CCL5. Am. J. Respir. Cell Mol. Biol., August 1, 2006; 35(2): 143 - 146. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
